News and Media

2017/03/30 – 2016 annual financial results and next development steps in 2017

30 March 2017
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced its 2016 annual financial results […]

2017/03/14 – Quantum Genomics announces positive data from new preclinical studies with QGC001

14 March 2017
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced positive results from preclinical studies of QGC001, its lead monotherapy candidate for the treatment of hypertension, demonstrating the absence […]

2017/02/20 – 2017 financial calendar – Quantum Genomics has joined the Pass French Tech program

20 February 2017
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today presented its financial calendar for 2017 and has joined the Pass French Tech program […]

2017/02/02 – Quantum Genomics granted key European patent for QGC011 combination therapy program

2 February 2017
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced the issuance of a key new patent by the European Patent Office […]